

Clean Version of Allowed Claims:

Claim 3. A composition comprising an isolated polypeptide consisting of an amino acid sequence consisting essentially of SEQ ID NO: 6, wherein the polypeptide is conjugated with at least one binding agent selected from the group consisting of a monoclonal antibody, single chain antibody, and phage-display evolved antibody.

Claim 5. A composition for treating prostate cancer, comprising an isolated polypeptide consisting of an amino acid sequence consisting essentially of SEQ ID NO: 6, conjugated with a binding agent capable of inhibiting binding of the polypeptide to its receptor, thereby inhibiting an ability of the polypeptide to induce prostate cancer cell growth, the binding agent selected from the group consisting of monoclonal antibody, fully humanized monoclonal antibody, polyclonal antibody, antibody selected by phage display selection, and single chain antibody.

Claim 7. An isolated polypeptide encoded by the DNA sequence of SEQ ID NO: 3.

Claim 11. The composition of Claim 3, wherein the at least one binding agent is conjugated with a reporter enzyme.

Claim 12. The composition of Claim 11, wherein the reporter enzyme is selected from the group consisting of alkaline phosphates and horseradish peroxidase.

Claim 13. The composition of Claim 3, wherein the at least one binding agent is tagged to a fluorophore.

Claim 14. The composition of Claim 3, wherein the at least one binding agent is tagged to a chemiluminescent compound or a radionuclide.

Claim 15. The composition of Claim 14, wherein the chemiluminescent compound comprises luciferase or green-fluorescent protein.

Do Not Enter
(Claims only)

Claim 16. The composition of Claim 3, wherein the polypeptide is conjugated with at least two binding agents selected from the group consisting of monoclonal antibodies, single chain antibodies, phage-display evolved antibodies, and in-vitro evolved antibodies, the at least two binding agents bound to different epitopes of the peptide such that binding of the first binding agent does not compromise binding of the second binding agent.

Claim 17. The composition of Claim 16, wherein at least one of the at least two binding agents is conjugated with a reporter enzyme.

Claim 18. The composition of Claim 17, wherein the reporter enzyme is selected from the group consisting of alkaline phosphates and horseradish peroxidase.

Claim 19. The composition of Claim 16, wherein at least one of the at least two binding agents is tagged to a fluorophore.

Claim 20. The composition of Claim 16, wherein at least one of the at least two binding agents is tagged to a chemiluminescent compound or a radionuclide.

Claim 21. The composition of Claim 20, wherein the chemiluminescent compound comprises luciferase or green-fluorescent protein.